Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Forsterova

R-Chop/R-Hdac and Rituximab Maintenance Results in High Complete Remission Rate, Minimal Residual Disease Negativity, and Excellent Survival in Elderly MCL Patients

Hematological Oncology

English

Related publications

First-Line Treatment of Inhl or MCL Patients With Br or R-Chop/R-Cvp: Results of the Bright 5-Year Follow-Up Study

Hematological Oncology

English

Rituximab Maintenance After Nordic Protocol (R-Maxichop/Hd-Arac/Asct) Significantly Prolongs Survival in Young Mantle Cell Lymphoma Patients

Hematological Oncology

English

Molecular Minimal Residual Disease Negativity and Decreased Stem Cell Mobilization Potential Predict Excellent Outcome After Autologous Transplant in NPM1 Mutant Acute Myeloid Leukemia.

Haematologica

Hematology

2019

English

Prognostic Value of Prior Consolidation in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation in Minimal Residual Disease-Negative First Complete Remission

American Journal of Hematology

Hematology

2018

English

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia

English

Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)

Hematological Oncology

English

Male Gender Is an Independent Predictor for Worse Survival and Relapse in a Large, Consecutive Cohort of Elderly DLBCL Patients Treated With R‐ CHOP

British Journal of Haematology

Hematology

2019

English

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Hematological Oncology

English

Anti-Infective Prophylaxis With Aciclovir and Cotrimoxazole Significantly Reduces the Rate of Infections and Therapy-Associated Deaths in Elderly Patients With DLBCL Undergoing R-Chop Immunochemotherapy

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Forsterova

R-Chop/R-Hdac and Rituximab Maintenance Results in High Complete Remission Rate, Minimal Residual Disease Negativity, and Excellent Survival in Elderly MCL Patients

Related publications

First-Line Treatment of Inhl or MCL Patients With Br or R-Chop/R-Cvp: Results of the Bright 5-Year Follow-Up Study

Rituximab Maintenance After Nordic Protocol (R-Maxichop/Hd-Arac/Asct) Significantly Prolongs Survival in Young Mantle Cell Lymphoma Patients

Molecular Minimal Residual Disease Negativity and Decreased Stem Cell Mobilization Potential Predict Excellent Outcome After Autologous Transplant in NPM1 Mutant Acute Myeloid Leukemia.

Prognostic Value of Prior Consolidation in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation in Minimal Residual Disease-Negative First Complete Remission

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)

Male Gender Is an Independent Predictor for Worse Survival and Relapse in a Large, Consecutive Cohort of Elderly DLBCL Patients Treated With R‐ CHOP

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Anti-Infective Prophylaxis With Aciclovir and Cotrimoxazole Significantly Reduces the Rate of Infections and Therapy-Associated Deaths in Elderly Patients With DLBCL Undergoing R-Chop Immunochemotherapy